Whitepaper

Remdesivir: A Classic Analysis of Desperate Measures During Desperate Times

Market Research

An analysis of the surge in demand for Remdesivir, as a COVID-19 drug. Was the surge driven by market preferences, perception, and push by few people? The rise of Remdesivir in 2020 is a classic example of what social media sentiments, medical data (or sales without medical data), and public perception are capable of doing in desperate times.

 

Key Points

  • In 2020, medical devices and surgical accessories suppliers registered losses as elective and non-elective surgeries were postponed extensively all over the US.
  • According to HHS, the US had secured >500,000 treatment courses of Remdesivir in September 2020. This has exhausted the stock of Gilead for 3 months.
  • Recently, HEOR has put the cost of COVID intensive-care treatment at around USD 20,000. If the drug shortens an ICU stay by 30%, then there might be a justification for a USD 5,000 price for the drug.

To know more...



Authors

Dr. Siddhartha Dutta

Dr. Sidhartha Dutta is a business technologist...

Related Topics

Whitepaper Emergence of Novel Immune Mediated Therapies

White Papers

Emergence of Novel Immune - Mediated Therapies

Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...

Technological Advancements

White Papers

Future Trends and Technological Advances in Vaccine...

The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...

Trends to Watch 2024 - Media Broadcast Tech

White Papers

2024 Trends to Watch -TV & Video Technology

Media enterprises are steadily witnessing margin pressures attributed to the emergence of newer audience engagement touchpoints such as FAST channels,...

VIEW MORE

We bring comprehensive data driven insights to everyone, everywhere